Skip to content

JBIO JBIO Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
Vera Therapeutics logo
Vera TherapeuticsVERA
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
Vor Biopharma logo
Vor BiopharmaVOR

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's deferred tax assets and other non-current assets?
JBIO (JBIO) reported deferred tax assets and other non-current assets of $69K in Q1 2026.
What is the long-term trend for JBIO's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), JBIO's deferred tax assets and other non-current assets has grown at a 7.1% compound annual growth rate (CAGR), from $49K to $69K.